Biotron (ASX:BIT) responds to ASX queries

Biotron Limited (ASX:BIT) has provided detailed responses to ASX queries regarding the BIT225-012 trial and a finance facility agreement. The company's Managing Director, Michelle Miller, addressed specific questions raised by ASX in relation to the trial's design, disclosure of trial limitations, delay in finalizing preliminary results, and the funding agreement. The responses aim to provide clarity and transparency regarding the trial and financial matters.

Executive Commentary on ASX Queries

The use of the word 'blood' in reference to viral loads was an oversight that had no bearing on the materiality of the trial's design or its outcomes. Biotron acknowledges the need for better proofreading of all releases and is committed to implementing improved processes to prevent typographical, spelling, and grammatical errors in the future. The company also explained the delay in finalizing the preliminary results, attributing it to unforeseen challenges such as workload, data queries, and a shortage of reagents from international suppliers. Furthermore, Biotron clarified that the limitations of the trial were disclosed in earlier announcements and emphasized the difficulty of demonstrating efficacy in small trials with specific participant criteria. The company confirmed that the information disclosed in the Results Announcement was considered to have a material effect on the price or value of its securities.

Summary of ASX Responses and Outlook

Biotron's responses to ASX queries provide insights into the trial's design, disclosure practices, and financial agreement. The company acknowledged oversight in the use of the word 'blood' in reference to viral loads and highlighted the need for improved proofreading processes. The delay in finalizing the preliminary results was attributed to unforeseen challenges, including workload, data queries, and a shortage of reagents. Biotron emphasized that the trial limitations were disclosed in earlier announcements and explained the difficulty of demonstrating efficacy in small trials with specific participant criteria. The company confirmed the material effect of the disclosed information on the price or value of its securities. Looking ahead, Biotron aims to enhance its disclosure practices and continue its commitment to transparency and compliance with ASX regulations.